CA1066620A - Composition and method of using a protein mixture derived from liver - Google Patents
Composition and method of using a protein mixture derived from liverInfo
- Publication number
- CA1066620A CA1066620A CA249,555A CA249555A CA1066620A CA 1066620 A CA1066620 A CA 1066620A CA 249555 A CA249555 A CA 249555A CA 1066620 A CA1066620 A CA 1066620A
- Authority
- CA
- Canada
- Prior art keywords
- acutalyn
- crude
- patient
- liver
- therapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 19
- 210000004185 liver Anatomy 0.000 title abstract description 25
- 108090000623 proteins and genes Proteins 0.000 title abstract description 13
- 102000004169 proteins and genes Human genes 0.000 title abstract description 13
- 238000000034 method Methods 0.000 title abstract description 12
- 239000003246 corticosteroid Substances 0.000 claims abstract description 11
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 28
- 229960000890 hydrocortisone Drugs 0.000 claims description 14
- 206010061218 Inflammation Diseases 0.000 claims description 7
- 230000004054 inflammatory process Effects 0.000 claims description 7
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 17
- 230000029663 wound healing Effects 0.000 abstract description 8
- 102000019197 Superoxide Dismutase Human genes 0.000 abstract description 6
- 108010012715 Superoxide dismutase Proteins 0.000 abstract description 6
- 229960001334 corticosteroids Drugs 0.000 abstract description 6
- 206010003246 arthritis Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 208000006454 hepatitis Diseases 0.000 abstract description 3
- 231100000283 hepatitis Toxicity 0.000 abstract description 3
- 230000031990 negative regulation of inflammatory response Effects 0.000 abstract description 3
- 231100000241 scar Toxicity 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 abstract description 2
- 230000004153 glucose metabolism Effects 0.000 abstract description 2
- 229940032362 superoxide dismutase Drugs 0.000 abstract 1
- 238000002347 injection Methods 0.000 description 28
- 239000007924 injection Substances 0.000 description 28
- 238000002560 therapeutic procedure Methods 0.000 description 26
- 241001465754 Metazoa Species 0.000 description 21
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 18
- 229940090044 injection Drugs 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 230000003902 lesion Effects 0.000 description 14
- 206010042674 Swelling Diseases 0.000 description 13
- 230000008961 swelling Effects 0.000 description 13
- 241000283086 Equidae Species 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 239000007788 liquid Substances 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 230000036407 pain Effects 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 229910021529 ammonia Inorganic materials 0.000 description 9
- 230000001684 chronic effect Effects 0.000 description 9
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 208000002260 Keloid Diseases 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 230000035876 healing Effects 0.000 description 7
- 210000001117 keloid Anatomy 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 241000283073 Equus caballus Species 0.000 description 6
- 206010023330 Keloid scar Diseases 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 206010052428 Wound Diseases 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 229910002092 carbon dioxide Inorganic materials 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 208000031481 Pathologic Constriction Diseases 0.000 description 5
- 230000008034 disappearance Effects 0.000 description 5
- 210000003918 fraction a Anatomy 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 206010010075 Coma hepatic Diseases 0.000 description 4
- 208000014311 Cushing syndrome Diseases 0.000 description 4
- 208000003251 Pruritus Diseases 0.000 description 4
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 4
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 4
- 229960002327 chloral hydrate Drugs 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 201000001059 hepatic coma Diseases 0.000 description 4
- 208000007386 hepatic encephalopathy Diseases 0.000 description 4
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 4
- 201000001988 urethral stricture Diseases 0.000 description 4
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 208000037171 Hypercorticoidism Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 210000000941 bile Anatomy 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000007803 itching Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000001338 necrotic effect Effects 0.000 description 3
- 230000001354 painful effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000004872 soft tissue Anatomy 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 208000037157 Azotemia Diseases 0.000 description 2
- 206010006811 Bursitis Diseases 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 206010055026 Prostatic obstruction Diseases 0.000 description 2
- 206010039580 Scar Diseases 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000002917 arthritic effect Effects 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000011443 conventional therapy Methods 0.000 description 2
- 230000009760 functional impairment Effects 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 229940105631 nembutal Drugs 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000001823 pruritic effect Effects 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 239000011369 resultant mixture Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000036642 wellbeing Effects 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 206010002536 Anisocytosis Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 101000623895 Bos taurus Mucin-15 Proteins 0.000 description 1
- 206010006803 Burns third degree Diseases 0.000 description 1
- 208000004434 Calcinosis Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 206010011655 Cushingoid Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000000624 Esophageal and Gastric Varices Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- 241001662043 Icterus Species 0.000 description 1
- 206010062315 Lipohypertrophy Diseases 0.000 description 1
- 208000032912 Local swelling Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 206010073261 Ovarian theca cell tumour Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical group N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 206010056091 Varices oesophageal Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- AYJRCSIUFZENHW-UHFFFAOYSA-L barium carbonate Inorganic materials [Ba+2].[O-]C([O-])=O AYJRCSIUFZENHW-UHFFFAOYSA-L 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- QTCANKDTWWSCMR-UHFFFAOYSA-N costic aldehyde Natural products C1CCC(=C)C2CC(C(=C)C=O)CCC21C QTCANKDTWWSCMR-UHFFFAOYSA-N 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 208000024170 esophageal varices Diseases 0.000 description 1
- 201000010120 esophageal varix Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000008921 facial expression Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000010200 folin Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 210000004124 hock Anatomy 0.000 description 1
- 210000002758 humerus Anatomy 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- ISTFUJWTQAMRGA-UHFFFAOYSA-N iso-beta-costal Natural products C1C(C(=C)C=O)CCC2(C)CCCC(C)=C21 ISTFUJWTQAMRGA-UHFFFAOYSA-N 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000013435 necrotic lesion Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 231100000857 poor renal function Toxicity 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000019525 primary metabolic process Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000011300 routine therapy Methods 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000036548 skin texture Effects 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 230000001148 spastic effect Effects 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000007460 surgical drainage Methods 0.000 description 1
- 208000001644 thecoma Diseases 0.000 description 1
- HLCHESOMJVGDSJ-UHFFFAOYSA-N thiq Chemical compound C1=CC(Cl)=CC=C1CC(C(=O)N1CCC(CN2N=CN=C2)(CC1)C1CCCCC1)NC(=O)C1NCC2=CC=CC=C2C1 HLCHESOMJVGDSJ-UHFFFAOYSA-N 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- CMPGARWFYBADJI-UHFFFAOYSA-L tungstic acid Chemical compound O[W](O)(=O)=O CMPGARWFYBADJI-UHFFFAOYSA-L 0.000 description 1
- 230000004143 urea cycle Effects 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/565,864 US4024247A (en) | 1971-12-27 | 1975-04-07 | Composition and method of using a protein mixture derived from liver |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1066620A true CA1066620A (en) | 1979-11-20 |
Family
ID=24260434
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA249,555A Expired CA1066620A (en) | 1975-04-07 | 1976-04-05 | Composition and method of using a protein mixture derived from liver |
Country Status (8)
| Country | Link |
|---|---|
| JP (1) | JPS51133407A (enrdf_load_stackoverflow) |
| AU (1) | AU1269976A (enrdf_load_stackoverflow) |
| BE (1) | BE840435A (enrdf_load_stackoverflow) |
| CA (1) | CA1066620A (enrdf_load_stackoverflow) |
| DE (1) | DE2614833A1 (enrdf_load_stackoverflow) |
| FR (1) | FR2306708A2 (enrdf_load_stackoverflow) |
| GB (1) | GB1529890A (enrdf_load_stackoverflow) |
| NL (1) | NL7603572A (enrdf_load_stackoverflow) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3150480B1 (fr) | 2023-06-27 | 2025-05-16 | Psa Automobiles Sa | Vehicule a propulsion electrique comprenant un systeme d’integration d’un cable de rechargement d’une batterie d’alimentation du moteur dudit vehicule |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2204409A1 (en) * | 1972-10-27 | 1974-05-24 | Palolab Pharmaceuti Als | Isolation of biologically active protein - with influence on primary carbohy-drate metabolism and the urea cycle and used to treat uraemia inflammation and shock |
-
1976
- 1976-04-05 CA CA249,555A patent/CA1066620A/en not_active Expired
- 1976-04-05 JP JP51038078A patent/JPS51133407A/ja active Pending
- 1976-04-06 DE DE19762614833 patent/DE2614833A1/de not_active Withdrawn
- 1976-04-06 FR FR7610004A patent/FR2306708A2/fr active Granted
- 1976-04-06 NL NL7603572A patent/NL7603572A/xx not_active Application Discontinuation
- 1976-04-06 AU AU12699/76A patent/AU1269976A/en not_active Expired
- 1976-04-06 BE BE165886A patent/BE840435A/xx unknown
- 1976-04-07 GB GB14147/76A patent/GB1529890A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| JPS51133407A (en) | 1976-11-19 |
| GB1529890A (en) | 1978-10-25 |
| BE840435A (fr) | 1976-08-02 |
| FR2306708B2 (enrdf_load_stackoverflow) | 1979-09-21 |
| FR2306708A2 (fr) | 1976-11-05 |
| NL7603572A (nl) | 1976-10-11 |
| DE2614833A1 (de) | 1976-10-21 |
| AU1269976A (en) | 1977-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Trippodo et al. | Partial chemical characterization of a natriuretic substance in rat atrial heart tissue | |
| Jacob et al. | Dimethyl sulfoxide (DMSO) toxicology, pharmacology, and clinical experience | |
| LYNN et al. | Morphine infusion after pediatric cardiac surgery | |
| US5318957A (en) | Method of stimulating angiogenesis | |
| US20010025057A1 (en) | Nitric oxide donor composition and method for treatment of anal disorders | |
| JP3721196B2 (ja) | 新生物疾患および自己免疫疾患の治療または予防のためのマグネシウムベースの製品の使用 | |
| US3224942A (en) | Anti-inflammatory, anti-edema and anti-thrombi drug | |
| INNERFIELD et al. | Fibrinolytic and anticoagulant effects of intravenous crystalline trypsin. | |
| JPH01503146A (ja) | 身体組織の治療方法および身体組織への医薬の投与方法 | |
| Pruet et al. | Management of the airway in patients with angioedema | |
| US4024247A (en) | Composition and method of using a protein mixture derived from liver | |
| CA1066620A (en) | Composition and method of using a protein mixture derived from liver | |
| Sheppeard et al. | INTRA-ARTICULAR OSMIC ACID IN RHEUMATOID ARTHRITIS: FIVE YEARS'EXPERIENCE | |
| US4753942A (en) | Method for the treatment of inflammatory conditions | |
| Lohse et al. | Studies on Pancreatic Stones: II. Citrate Secretion in the Canine Pancreatic Juice | |
| NAKAMURA et al. | Prolonged neuromuscular blockade following trimetaphan infusion: A case report and in vitro study of cholinesterase inhibition | |
| Walton | Flaxedil, a new curarizing agent | |
| Saarnivaara | Comparison of paracetamol and pentazocine suppositories for pain relief after tonsillectomy in adults | |
| KR20000065178A (ko) | 허혈-재관류손상을치료또는예방하는방법 | |
| Sorenson et al. | A Synthetic Anticoagulant: A Polysulfuric Acid Ester of Polyanhydromannuronic Acid (Paritol) Experience with Its Use in Man | |
| Lund et al. | AN EVALUTION of Epidural Analgesia in Geriatric Surgery | |
| RU2817988C1 (ru) | Способ восстановления функционального состояния печени при тяжёлом остром панкреатите | |
| Isoa | Current trends in the management of sickle cell disease: an overview | |
| EP0213072A2 (en) | Treatment of chronic imflammatory disease | |
| RU2157208C2 (ru) | Препарат для лечения отморожений |